Correction of G551D‐CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB‐07
- 1 October 2002
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (4) , 504-512
- https://doi.org/10.1038/sj.bjp.0704882
Abstract
This study compares the effect of three chemically unrelated cystic fibrosis transmembrane conductance regulator (CFTR) activators on epithelial cell monolayers expressing the G551D‐CFTR mutant. We measured Cl− transport as the amplitude of short‐circuit current in response to the membrane permeable cAMP analogue 8‐(4‐chlorophenylthio)adenosine‐3′‐5′‐cyclic monophosphate (CPT‐cAMP) alone or in combination with a CFTR opener. The correction of G551D‐CFTR defect was quantified by comparison with maximal activity elicited in cells expressing wild type CFTR. To this end we used Fisher rat thyroid (FRT) cells transfected with wild type or G551D CFTR, and primary cultures of human nasal epithelial cells. In both types of epithelia, cAMP caused activation of Cl− transport that was inhibited by glibenclamide and not by 4,4′‐diisothiocyanato‐stilbene‐2,2′‐disulfonic acid. After normalising for CFTR expression, the response of FRT‐G551D epithelia was 1% that of wild type monolayers. Addition of genistein (10–200 μM), but not of 8‐cyclopentyl‐1,3‐dipropylxanthine (CPX, 1–100 μM) or of the benzo[c]quinolizinium MPB‐07 (10–200 μM) to FRT‐G551D epithelia pre‐treated with cAMP, stimulated a sustained current that at maximal genistein concentration corresponded to 30% of the response of wild type epithelia. The genistein dose‐response curve was bell‐shaped due to inhibitory activity at the highest concentrations. The dose‐dependence in G551D cells was shifted with respect to wild type CFTR so that higher genistein concentrations were required to observe activation and inhibition, respectively. On human nasal epithelia the correction of G551D‐CFTR defective conductance obtained with genistein was 20% that of wild type. The impressive effect of genistein suggests that it might correct the Cl− transport defect on G551D patients. British Journal of Pharmacology (2002) 137, 504–512. doi:10.1038/sj.bjp.0704882Keywords
This publication has 31 references indexed in Scilit:
- Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytesBritish Journal of Pharmacology, 2000
- ATP Hydrolysis by a CFTR Domain: Pharmacology and Effects of G551D MutationBiochemical and Biophysical Research Communications, 2000
- Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genisteinBiochemical Journal, 1999
- Direct Activation of Cystic Fibrosis Transmembrane Conductance Regulator Channels by 8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-Diallyl-8-cyclohexylxanthine (DAX)Published by Elsevier ,1998
- 8-Cyclopentyl-1,3-dipropylxanthine and Other Xanthines Differentially Bind to the Wild-Type and ΔF508 Mutant First Nucleotide Binding Fold (NBF-1) Domains of the Cystic Fibrosis Transmembrane Conductance RegulatorBiochemistry, 1997
- ATPase Activity of the Cystic Fibrosis Transmembrane Conductance RegulatorJournal of Biological Chemistry, 1996
- Modulation of Cl− secretion in rat distal colon by genistein, a protein tyrosine kinase inhibitorEuropean Journal of Pharmacology, 1996
- The Irish cystic fibrosis database.Journal of Medical Genetics, 1995
- Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding.Journal of Clinical Investigation, 1994
- Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosisNature Genetics, 1992